Alnylam Pharmaceuticals Inc (ALNY)
257.91
-6.69
(-2.53%)
USD |
NASDAQ |
Nov 14, 16:00
256.21
-1.70
(-0.66%)
After-Hours: 20:00
Alnylam Pharmaceuticals Net Income (TTM): -332.26M for Sept. 30, 2024
Net Income (TTM) Chart
Historical Net Income (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | -332.26M |
| June 30, 2024 | -72.94M |
| March 31, 2024 | -332.08M |
| December 31, 2023 | -440.24M |
| September 30, 2023 | -509.86M |
| June 30, 2023 | -1.064B |
| March 31, 2023 | -1.065B |
| December 31, 2022 | -1.131B |
| September 30, 2022 | -1.182B |
| June 30, 2022 | -980.72M |
| March 31, 2022 | -892.87M |
| December 31, 2021 | -852.82M |
| September 30, 2021 | -837.90M |
| June 30, 2021 | -886.68M |
| March 31, 2021 | -876.35M |
| December 31, 2020 | -858.28M |
| September 30, 2020 | -890.93M |
| June 30, 2020 | -846.17M |
| March 31, 2020 | -886.42M |
| December 31, 2019 | -886.12M |
| September 30, 2019 | -821.37M |
| June 30, 2019 | -858.12M |
| March 31, 2019 | -802.20M |
| December 31, 2018 | -761.50M |
| September 30, 2018 | -692.28M |
| Date | Value |
|---|---|
| June 30, 2018 | -569.94M |
| March 31, 2018 | -524.80M |
| December 31, 2017 | -490.87M |
| September 30, 2017 | -461.58M |
| June 30, 2017 | -442.72M |
| March 31, 2017 | -414.42M |
| December 31, 2016 | -410.11M |
| September 30, 2016 | -387.90M |
| June 30, 2016 | -360.62M |
| March 31, 2016 | -342.27M |
| December 31, 2015 | -290.07M |
| September 30, 2015 | -220.74M |
| June 30, 2015 | -187.94M |
| March 31, 2015 | -160.23M |
| December 31, 2014 | -360.40M |
| September 30, 2014 | -371.36M |
| June 30, 2014 | -357.06M |
| March 31, 2014 | -331.16M |
| December 31, 2013 | -89.22M |
| September 30, 2013 | -119.06M |
| June 30, 2013 | -108.87M |
| March 31, 2013 | -103.66M |
| December 31, 2012 | -106.01M |
| September 30, 2012 | -58.13M |
| June 30, 2012 | -51.86M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (TTM) Range, Past 5 Years
-1.182B
Minimum
Sep 2022
-72.94M
Maximum
Jun 2024
-791.22M
Average
-881.23M
Median
Net Income (TTM) Benchmarks
| Pfizer Inc | 4.252B |
| BridgeBio Pharma Inc | -453.82M |
| Biomarin Pharmaceutical Inc | 322.29M |
| Gilead Sciences Inc | 126.00M |
| Regeneron Pharmaceuticals Inc | 4.654B |